The Medicinal Chemistry Core is a newly proposed CCSG Core. The Medicinal Chemistry Core Laboratory was developed to provide the needed expertise in the area of synthesis of small molecules, modified peptides and bioconjugates for biomedical research by the Cancer Center research community. Creation of this Core was in direct response to a clearly defined need for providing synthesis of chemical reagents needed for preclinical studies (not for clinical drug development). The guiding principle was that the Center was not attempting to establish a GMP chemical production facility, but a chemical synthesis core laboratory to provide reagent grade compounds for use in validation and proof-of-principle target discovery studies. To accomplish this, there are a large number of investigators within the Center who have a need for a Medicinal Chemistry Core to provide unique reagents. These reagents are needed both for the study of the role of specific molecular targets controlling the growth and survival of cancer cells, as well as for the development of related reagents for cancer treatment. From the 2002 inception of the Medicinal Chemistry Core, its mission has been to provide very specific unique reagents to allow proof of principle and general drug discovery studies and accelerate basic sciences studies. The main purpose of the Medicinal Chemistry Core is: (1) To design and synthesize bioactive molecules in the most cost effective manner possible. (2) To optimize methods of purification of bioactive molecules at high yield. (3) To provide NMR, Mass spectrometry, and HPLC analysis for characterization of new anticancer agents. (4) To provide investigators with custom synthesis of anticancer agents in amounts ranging from milligrams to grams. (5) To provide experience and intuition for identification and optimization of lead compounds as well as promising reagents. This application requests support for a resource which continues to fulfill an essential role for peer reviewed research within the SKCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-48
Application #
8117673
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
48
Fiscal Year
2010
Total Cost
$172,865
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Johnson, Renee M; Fleming, Charles B; Cambron, Christopher et al. (2018) Race/Ethnicity Differences in Trends of Marijuana, Cigarette, and Alcohol Use Among 8th, 10th, and 12th Graders in Washington State, 2004-2016. Prev Sci :
Marrone, Kristen A; Zhou, Xian; Forde, Patrick M et al. (2018) A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. Oncologist 23:859-865
Bar-Shir, Amnon; Alon, Lina; Korrer, Michael J et al. (2018) Quantification and tracking of genetically engineered dendritic cells for studying immunotherapy. Magn Reson Med 79:1010-1019
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Dean, Lorraine T; Nicholas, Lauren Hersch (2018) Using Credit Scores to Understand Predictors and Consequences of Disease. Am J Public Health 108:1503-1505
Litvak, Anya; Batukbhai, Bhavina; Russell, Stuart D et al. (2018) Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer 124:1904-1911
Kandala, Sri Kamal; Liapi, Eleni; Whitcomb, Louis L et al. (2018) Temperature-controlled power modulation compensates for heterogeneous nanoparticle distributions: a computational optimization analysis for magnetic hyperthermia. Int J Hyperthermia :1-15
Adler, B L; Pezhouh, M K; Kim, A et al. (2018) Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med 283:568-577
Anchoori, Ravi K; Jiang, Rosie; Peng, Shiwen et al. (2018) Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer. ACS Omega 3:11917-11929

Showing the most recent 10 out of 2393 publications